FDA Accepts Genentech’s sBLA for Lunsumio-Polivy Combo in Relapsed Lymphoma
Event summary
- FDA accepted Genentech’s sBLA for Lunsumio VELO (mosunetuzumab-axgb) + Polivy (polatuzumab vedotin-piiq) combo for relapsed/refractory large B-cell lymphoma (LBCL).
- Phase III SUNMO study showed 59% reduction in disease progression/death risk vs. R-GemOx, with median PFS of 11.5 months vs. 3.8 months.
- FDA decision expected by February 9, 2027; combo offers chemotherapy-free, outpatient treatment option.
- Lunsumio is part of Genentech’s CD20xCD3 bispecific antibody program, with ongoing trials in follicular lymphoma.
The big picture
Genentech’s sBLA acceptance for the Lunsumio-Polivy combo underscores the growing role of bispecific antibodies in hematologic malignancies. The FDA’s decision will impact the competitive landscape for relapsed/refractory LBCL treatments, where chemotherapy-free options are increasingly sought after. The combo’s potential to reduce treatment delays and improve access for patients in community settings aligns with broader trends in oncology toward decentralized care.
What we're watching
- Regulatory Timeline
- Whether the FDA will approve the Lunsumio-Polivy combo by the February 2027 PDUFA date, given the strong Phase III data.
- Market Adoption
- The pace at which community oncologists adopt this chemotherapy-free, outpatient treatment for relapsed/refractory LBCL.
- Commercial Strategy
- How Genentech positions this combo against existing therapies, particularly in the second-line setting where treatment delays can be critical.
Related topics